Phase 3 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 50 or older who are able to give written consent to participate
- People who have a specific type of age-related macular degeneration (AMD) causing abnormal blood vessel growth beneath the central part of the retina, confirmed by specialist eye scans, and who have not yet received any treatment for it
- People where the abnormal blood vessel area makes up more than half of the total affected area in the eye being studied
- People whose vision in the study eye falls within a specific range on a standard eye chart test (confirm with trial site for exact letter score thresholds)
- People who have fluid in or under the retina at the central area of the eye, as shown on specialist eye scans, caused by the abnormal blood vessel growth
Who may not be able to join:
- People whose total affected area in the study eye is larger than 12 disc areas (a measurement used by eye specialists)
- People who have scarring, fibrous tissue, or tissue loss affecting the central part of the retina in the study eye
- People where scarring or fibrous tissue makes up more than half of the total affected area in the study eye
- People who have tears or rips in a specific layer of the retina (the retinal pigment epithelium) in the central retinal area of the study eye
- People who have had bleeding inside the eye within the 4 weeks before the study randomisation date
- People whose abnormal blood vessel growth is caused by conditions other than AMD, such as severe short-sightedness, certain eye infections, or other specific eye conditions
- People with uncontrolled glaucoma in the study eye, meaning eye pressure remains above a certain level even with medication
- People with a history of diabetic eye disease, diabetic swelling of the retina, certain inflammatory eye conditions, or any other blood vessel disease affecting the retina in either eye
- People with signs of active infection or inflammation in or around either eye at the time of screening or at the start of the study
- People with uncontrolled blood pressure, or whose blood pressure has not been stable for at least 12 weeks before screening
- People who have previously received or are currently receiving any anti-VEGF injections or similar treatments for AMD in the study eye, or who have had surgery for AMD in the study eye (vitamin or dietary supplements are excepted)
- People with any other significant health condition, disorder, or abnormal test result that the study doctor believes could affect participant safety or the reliability of the study results
- Other criteria as specified in the study protocol (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MD, Amgen
Phone: 866-572-6436
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.